Slow Transit Constipation (STC) Model

Model Description

Slow transit constipation (STC) is a functional gastrointestinal disorder characterized by delayed colonic motility, reduced bowel movements, and hardened stools due to excessive water absorption. Our loperamide-induced STC model replicates human pathophysiology through:

• Opioid receptor-mediated gut hypomotility
• Reduced fecal output (≥50% decrease vs controls)
• Increased colonic transit time (≥2x baseline)

Clinical Relevance:
✓ Mimics refractory STC: Poor response to conventional laxatives
✓ Drug development utility: Validated with prokinetic agents (e.g., mosapride)

Applications

• Prokinetic drug efficacy evaluation
• Enteric nervous system (ENS) function studies
• Gut microbiome-motility interaction research
• Novel laxative mechanism exploration

Modeling Protocol —— 14-Day Loperamide Induction

1. Group Design:

• Normal Group: 0.5% CMC-Na solution (oral gavage)
• Model Group: Loperamide HCl 5 mg/kg (oral gavage)
• Treatment Group: Loperamide + mosapride (post 3h administration)

2. Procedure:

• Days 1-14: Daily dosing (9:00 AM)
• Fecal monitoring: Collect 24h output on Days 7/14

3. Terminal assessment: Intestinal transit rate via carmine red dye

Validation & Testing

Technical Advantages

Data

Figure 1 Comparison of 24-hour feces output, fecal water content (%), and intestinal propulsion rate (%) among mice in various groups